| Former United States Secretary Of Defense Also Takes 4.1% Stake in
Company
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS
- News;
DAX:PJT), a bio-therapeutics Company dedicated to the commercialization
of products for a variety of malignant, degenerative and auto-immune
indications, announced today that Frank Carlucci, former US Defense
Secretary, will be heading the Company's Strategic Business Advisory
Board.
Mr. Carlucci is Chairman Emeritus of The Carlyle Group, after serving
as Chairman from 1992 to 2003.
Mr. Carlucci commented, "Pluristem's technology has the potential to
be very beneficial in areas such as bone-marrow transplantation,
Parkinson's Disease and heart disease, among others."
Pluristem's Chairman and CEO, Mr. Zami Aberman, said, "We are honored
to have Frank Carlucci heading our Strategic Business Advisory Board,
and are very pleased that Mr. Carlucci has taken a 4.1% stake in
Pluristem Life Sciences as part of our recently announced $13.5 million
financing."
About Pluristem:
Pluristem Life Systems, Inc. is a Company dedicated to the
commercialization of non-personalized (allogeneic) stem cell therapy
products for the treatment of numerous severe degenerative, malignant
and autoimmune disorders. The Company's first planned product, PLX-BMT,
targets a $2 billion market and is intended to resolve the global
shortfall of matched tissue for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem cells (HSCs) contained
in umbilical cord blood (CB).
Pluristem's products are derived from mesenchymal stem cells (MSCs)
obtained from the placenta and expanded in the Company's proprietary
PluriX(TM) 3D bioreactor that imitates the natural microstructure of
bone marrow and does not require supplemental growth factors, cytokines
or other exogenous materials. Pluristem believes the resultant expanded
cells, termed PLX cells, are multipotent and able to differentiate into
a variety of cell types as well as being immune-privileged to protect
the recipient from immunological reactions that often accompanies
transplantation. Pluristem believes their future products will
participate in the approximate $30 billion therapeutic and regenerative
cellular market.
Pluristem has offices and is incorporated in the USA with research
and manufacturing facilities in Israel.
www.pluristem.com
Safe Harbor Statement This press release contains statements, which
may constitute "forward-looking statements" regarding our intent, belief
or current expectations. Forward-looking statements in this release
include that Pluristem's technology has the potential to be very
beneficial in areas such as bone-marrow transplantation, Parkinson's
Disease and heart disease, among others; Factors that could prevent our
forward looking statements from being achieved include that we may be
unable to get regulatory approval for our products; we may be
unsuccessful in developing any products; our technology may not be
validated as we progress further and our methods may not be accepted by
the scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; results in the laboratory may not translate to equally good
results in real surgical settings; our patents may not be sufficient to
protect essential aspects of our technology; competitors may invent
better technology; our products may not work as well as hoped or worse,
our products may harm recipients; and we may not be able to raise funds
for development or working capital when we require it. As well, our
products may never develop into useful products and even if they do,
they may not be approved for sale to the public. For further risk
factors see the Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
